$10.10 -0.71 (-6.55%)

Alto Neuroscience Inc. (ANRO)

Alto Neuroscience Inc. (ANRO) is a clinical-stage biotechnology company focused on developing precision neurology treatments. Leveraging advanced neurotechnology and data-driven insights, Alto aims to create personalized therapies for psychiatric and neurological disorders, including depression and anxiety, with an emphasis on improving patient outcomes through targeted interventions.

🚫 Alto Neuroscience Inc. does not pay dividends

Company News

ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire Inc. • Bragar Eagel & Squire, P.C. • October 7, 2025

Law firm investigating potential claims against Alto Neuroscience after stock price dropped 69.99% following disappointing Phase 2b trial results for ALTO-100 depression treatment.

Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal
Benzinga • Vandana Singh • June 3, 2025

Alto Neuroscience acquired a portfolio of dopamine agonist drug combinations for treatment-resistant depression from Chase Therapeutics, including the advanced program ALTO-207, which showed significant improvements in depression symptoms in a Phase 2a trial.

Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions
Zacks Investment Research • Zacks Equity Research • April 9, 2024

Alto Neuroscience (ANRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Wall Street hungry for IPO of Mexican supermarket chain BBB Foods as stock rises 9%
MarketWatch • MarketWatch • February 9, 2024

BBB Foods’ stock rises in its first day of trading as IPO market churns out deals.

TBBBKYTXPMNTGUTS